Polyphenols enhance the activity of alkylating agents in leukaemia cell lines by Mahbub, Amani A. et al.
Polyphenols enhance the activity of alkylating agents in 
leukaemia cell lines
MAHBUB, Amani A. <http://orcid.org/0000-0003-2055-5815>, LE MAITRE, 
Christine <http://orcid.org/0000-0003-4489-7107>, HAYWOOD-SMALL, Sarah 
<http://orcid.org/0000-0002-8374-9783> and CROSS, Neil 
<http://orcid.org/0000-0003-2055-5815>
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/24961/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
MAHBUB, Amani A., LE MAITRE, Christine, HAYWOOD-SMALL, Sarah and 
CROSS, Neil (2019). Polyphenols enhance the activity of alkylating agents in 
leukaemia cell lines. Oncotarget, 10 (44). 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Oncotarget4570www.oncotarget.com
Polyphenols enhance the activity of alkylating agents in leukaemia 
cell lines
Amani A. Mahbub1, Christine L. Le Maitre2, Sarah Haywood-Small2, Neil A. Cross2 and 
Nicola Jordan-Mahy2 
1Faculty of Applied Medical Sciences, Laboratory Medicine Department, Umm Al Qura University, Makkah, Saudi Arabia
2Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK 
Correspondence to: Nicola Jordan-Mahy, email: n.jordan-mahy@shu.ac.uk
Keywords: leukaemia; cisplatin; cyclophosphamide; chlorambucil; polyphenols
Received: April 10, 2019    Accepted: June 10, 2019     Published: July 16, 2019
Copyright: Mahbub et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Polyphenols have been shown to sensitize solid tumours to alkylating agents 
such as cisplatin, and induce apoptosis and/or cell-cycle arrest. Here, we assess the 
effects of five polyphenols alone and in combination with three alkylating agents: 
cisplatin, cyclophosphamide and chlorambucil in lymphoid and myeloid leukaemia 
cells lines, and non-tumour control cells. 
In lymphoid leukaemia cell lines there was a synergistic reduction in ATP and 
glutathione levels, an induction of cell cycle arrest, DNA damage and apoptosis 
when quercetin, apigenin, emodin and rhein were combined with cisplatin and 
cyclophosphamide; and when apigenin and rhein were combined with chlorambucil. In 
myeloid leukaemia cells quercetin, apigenin and emodin showed a similar synergistic 
effect with all alkylating agents; however antagonistic effects were observed with 
some or all alkylating agents when combined with emodin, rhein and cis-stilbene. All 
synergistic effects were associated with reduced glutathione levels, DNA damage and 
apoptosis; whilst during antagonism the reverse effects were observed. 
The combination of alkylating agents, particularly cisplatin with polyphenols could 
be promising for the treatment of lymphoid leukaemias, with apigenin showing the 
greatest effects. Likewise in myeloid cells apigenin also synergised the action of all 
alkylating agents, suggesting that apigenin may also be beneficial in myeloid leukaemias.
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INTRODUCTION
Leukaemia affects millions of people worldwide 
each year and mortality rates are high, despite advances 
in chemotherapy treatments [1, 2]. Alkylating agents 
such as cisplatin, cyclophosphamide and chlorambucil 
are major chemotherapeutic agents used for the treatment 
of leukaemia [1, 2]. Mechanistically, these agents form 
DNA cross-links, resulting in inhibition of DNA synthesis, 
cell cycle arrest and induction of apoptosis [3, 5, 6]. 
Unfortunately, the use of alkylating agents is commonly 
associated with many side effects including: nausea, 
vomiting, hearing loss, nephrotoxicity, myelosuppression 
and immunosuppression, all of which commonly occur in 
leukaemia patients [2–8]. 
Furthermore, alkylating agents are themselves 
mutagenic, teratogenic and carcinogenic; with 
cyclophosphamide use, being linked to an increased risk of 
acute myeloid leukaemia, skin and bladder cancer [2, 3, 9, 
10]. Drug resistance is also a major problem, which results 
from increased DNA repair mechanisms; a decrease in 
cell permeability and/or an increase in glutathione levels, 
which subsequently protects against DNA damage [2, 6, 
8]. Thus, systemic toxicity and drug resistance are major 
problems in limiting the effect of alkylating agents. For 
this reason, novel strategies and therapeutics for leukaemia 
are urgently needed.
Our previous work has demonstrated that bioactive 
compounds such as polyphenols (quercetin, apigenin, 
emodin, rhein, and cis-stilbene) show promise as anti-
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cancer agents in leukaemia cells lines [11], whilst having 
a protective effect on normal haematopoietic cells. 
These selected polyphenols are representatives of the 
major classification of polyphenols, and are commonlly 
found in fruits (e.g. apples, blueberries and grapes) and 
vegetables (e.g. onions, broccoli, and rhubarb) [12–14]. 
These polyphenols are also associated with improved 
quality of life [15] and improved outcomes in cancer 
patients [16]. 
Furthermore, our prior work demonstrated 
polyphenols synergistically enhanced the action of 
topoisomerase inhibitor agents (doxorubicin and 
etoposide), reducing ATP levels and inducing apoptosis 
in lymphoid and myeloid leukaemia cell lines; whilst 
protecting normal hematopoietic stem cells [17]. Anti-
tumour actions of alkylating agents such as cisplatin are 
reported to be potentiated by polyphenols in solid tumour 
cell lines [18–24], and evidence to date generally support 
the notion that polyphenols promote the pro-apoptotic 
activity of alkylating agents. 
Thus, this study investigated whether the most 
potent anti-proliferative and pro-apoptotic polyphenols 
(quercetin, apigenin, emodin, and cis- stilbene) [11, 17] 
synergistically enhance the actions of alkylating agents 
(cisplatin, cyclophosphamide and chlorambucil) in 
leukaemia cell lines. Effects on ATP levels, apoptosis 
and cell cycle progression were measured in lymphoid 
and myeloid leukaemia cell lines and two normal 
hematopoietic cells. Furthermore, potential mechanisms 
of action of combination treatments were investigated by 
determining caspase 8 and 9 activity, glutathione levels, 
and DNA damage.
RESULTS
The effect of alkylating agents alone on ATP 
levels and caspase 3 activity 
Cisplatin, cyclophosphamide and chlorambucil 
decreased ATP levels as a marker of cellular activity and 
viability, and increased caspase 3 activity as a marker of 
apoptotic signalling in all cell lines in a dose-dependent 
manner compared to non-tumour haematopoietic cells 
(Supplementary Figure 1). The lowest significant dose 
(LSD) and IC50 doses at which ATP levels were reduced 
at 24 h in response to cisplatin, cyclophosphamide and 
chlorambucil alone, differed between cell lines (Table 1). 
Treatment doses between 0.01 μM and 2 μM of 
cisplatin; 0.4 μM and 50 μM of cyclophosphamide; 0.01 
μM and 10 μM of chlorambucil significantly reduced 
ATP levels after 24 h treatment in lymphoid and myeloid 
leukaemia cell lines, and the non-tumour control cells 
(P ≤ 0.05) (Supplementary Figure 1 and Table 1). KG1a 
myeloid cells were the most resistant cells, particularly to 
cyclophosphamide, with ATP levels significantly reduced 
only at a treatment dose of 50 μM (Table 1).
The LSDs for the induction of caspase 3 activity for 
cisplatin, cyclophosphamide and chlorambucil followed 
a similar pattern to the LSDs for ATP levels (Table 1). 
Once again, KG1a cells were the most resistant cells to 
cyclophosphamide (Supplementary Figure 1 and Table 1). 
The LSDs that significantly increased caspase 3 activity 
were the same, or slightly higher than those for ATP 
levels, this reflects the progression from a reduction of cell 
viability to early apoptosis (Table 1). These LSDs were 
subsequently used to analyse the effects of combination 
treatments and determine whether polyphenols had a 
synergistic or antagonistic effects on the activity of 
alkylating agents.
The effect of combination treatments on ATP 
levels and caspase 3 activity 
All three alkylating agents significantly reduced 
ATP levels (Supplementary Figure 2) and induced 
caspase 3 activity in all leukaemia cell lines (P ≤ 0.05) 
(Supplementary Figure 3).  However, the action of 
the alkylating agents was significantly affected when 
used in combination with polyphenols. Most notably, 
apigenin was shown to synergistically enhance the action 
of cyclophosphamide and chlorambucil; significantly 
decreasing ATP levels and increasing caspase 3 activity in 
both lymphoid and myeloid leukaemia cell lines (P ≤ 0.05) 
(Supplementary Figures 2 and 3); shown here in the Jurkat 
and the THP-1 leukaemia cell lines (Figures 1 and 2). 
Combined treatment with quercetin and cisplatin 
synergistically reduced ATP levels and increased caspase 
3 activity in all lymphoid and myeloid leukaemia cell 
lines (Supplementary Figures 2 and 3), shown here in 
Jurkat and THP-1 cells (Figures 1 and 2). Similarly 
quercetin enhanced cyclophosphamide responses in the 
lymphoid cell lines Jurkat (Figure 1) and CCRF-CEM 
(P ≤ 0.05) (Supplementary Figures 2 and 3). Emodin 
also synergistically enhanced the action of cisplatin and 
cyclophosphamide in all lymphoid cell lines (P ≤ 0.05) 
(Figure 1, Supplementary Figures 2 and 3), but had 
no significant effects in myeloid cell lines (Figure 2, 
Supplementary Figures 2 and 3). 
Rhein was shown to synergize the action of all 
three alkylating agents in both lymphoid cell lines: 
Jurkat (Figure 1) and CCRF-CEM cells (Supplementary 
Figures 2 and 3), causing a significant decrease in ATP 
levels and an increase in caspase 3 activity (P ≤ 0.05). 
In contrast, in myeloid cell lines rhein antagonized all 
three alkylating agents in THP-1 cells (Figure 2), and 
cyclophosphamide and chlorambucil in KG-1a cells 
(Supplementary Figures 2 and 3); resulting in an increase 
in ATP levels and cell survival (P ≤ 0.05).  Finally, cis-
stilbene was shown to synergize only cisplatin in Jurkat 
(Figure 1) and CCRF-CEM cells (Supplementary Figures 
2 and 3) (P ≤ 0.05); whilst having an antagonistic effect 
with cyclophosphamide in lymphoid cells (Figure 1, 
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Supplementary Figures 2 and 3); with all three alkylating 
agents in THP-1 cells (Figure 2) and with chlorambucil in 
KG1a cells (Supplementary Figures 2 and 3) (P ≤ 0.05). 
In non-tumour haematopoietic control cells 
(CD133+HSC and CD34+HSC), all polyphenols 
antagonised the action of all alkylating agents, significantly 
increasing both ATP levels and cell survival (P ≤ 0.05) 
(Figure 3, Supplementary Figures 2 and 3). The effects of 
all combination treatments on apoptosis were confirmed 
by assessment of nuclear morphology in all cell lines 
(Supplementary Figures 4 and 5). 
The effects of combination treatment on caspase 
8 and 9 activity
When quercetin or apigenin were combined with 
cisplatin or cyclophosphamide, both caspase 8 and 9 
activity were synergistically increased in all investigated 
leukaemia cell lines, consistent with caspase 3 and nuclear 
morphological assessments shown previously (P ≤ 0.05) 
(Figure 4). In contrast, emodin and rhein when used with 
cisplatin or cyclophosphamide only increased in caspase 9 
activity in lymphoid leukaemia cells (P ≤ 0.05) (Figure 4); 
whereas cis-stilbene combined with cisplatin increased in 
caspase 8 and 9 activity, but only in lymphoid leukaemia 
cell lines (P ≤ 0.05) (Figure 4).  
The effect of combination treatments on cell 
cycle progression 
In the lymphoid leukaemia cell lines, quercetin 
and apigenin were shown to have an interactive effect 
when combined with each alkylating agent, causing the 
accumulation of cells within S phase of cell cycle (P ≤ 0.05) 
(Supplementary Figures 6, 7 and  Table 2). In myeloid cell 
lines, quercetin and apigenin treatment in combination with 
alkylating agents resulted in accumulation of cells in G2/M 
and/or S phase of the cell cycle (P ≤ 0.05) (Supplementary 
Figures 6 and 7, Table 2). The only exception was when 
quercetin and cyclophosphamide were combined in myeloid 
cell lines, where an antagonistic effect was observed with 
no cell cycle arrest (P ≤ 0.05) (Supplementary Figure 6 and 
Table 2).   
When emodin and rhein were used in combination with 
each alkylating agent, an interactive effect was observed, with 
an accumulation of cells in G0/G1 or S phase of the cell cycle 
in lymphoid cell lines (P ≤ 0.05) (Supplementary Figures 8, 
9 and Table 2), whilst in the myeloid cell lines, both emodin 
and rhein antagonised the alkylating agent-induced cell cycle 
arrest (P ≤ 0.05) (Table 2). However, when emodin was used 
in combination with chlorambucil in myeloid cell lines, an 
interactive effect was observed with S and/or G2/M phase cell 
cycle arrest (P ≤ 0.05) (Table 2). 
Table 1: The lowest significant dose (LSDs) and IC50 doses of cisplatin (CSP), cyclophosphamide (CYCLO) and 
chlorambucil (CLB) which reduced ATP levels and increased caspase 3 activity (CASP 3) when compared to the 
vehicle control (P ≤ 0.05) in two lymphoid (Jurkat and CCRF-CEM) and two myeloid (THP1 and KG-1a) leukaemia 
cell lines; and two non-tumour control hematopoietic stem cells (CD34+ HSCs and CD133+ HSCs)
Cell type Doses
CSP CYCLO CLB
ATP CASP 3 ATP CASP 3 ATP CASP 3
Lymphoid 
Cells
Jurkat
LSD 0.01 µM 0.01 µM 2 µM 10 µM 10 µM 10 µM
IC50 0.4 µM 4.5 µM >50 µM 50 µM >50 µM >50 µM
CCRF-
CEM
LSD 2 µM 0.4 µM 10 µM 10 µM 0.01 µM 10 µM
IC50 15 µM 6 µM >50 µM >50 µM 6.5 µM >50 µM
Myeloid 
Cells
THP1
LSD 0.01 µM 0.01 µM 0.4 µM 2 µM 0.4 µM 0.4 µM
IC50 5.5 µM 5 µM >50 µM >50 µM >50 µM >50 µM
KG1a
LSD 2 µM 2 µM 50 µM 50 µM 10 µM 10 µM
IC50 >50 µM >50 µM >50 µM >50 µM >50 µM >50 µM
Non-Tumor 
Control 
Cells
CD34+  
HSCs
LSD 0.4 µM 0.4 µM 2 µM 2 µM 2 µM 10 µM
IC50 10 µM >50 µM >50 µM >50 µM 40 µM >50 µM
CD133+ 
HSCs
LSD 0.4 µM 2 µM 10 µM 10 µM 10 µM 10 µM
IC50 40 µM 30 µM >50 µM >50 µM >50 µM >50 µM
The LSDs for ATP levels where used in subsequent investigation of combination treatments on cell-cycle progression, ATP 
and glutathione levels and DNA damage. The LSDs for caspase 3 activity were used for further investigation of apoptosis.
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Figure 1: The effect of cisplatin (CSP), cyclophosphamide (CYCLO) and chlorambucil (CLB) when used in combination with quercetin 
(QUE), apigenin (AP), emodin (EMO), rhein (RH) or cis-stilbene (CIS) on (A) ATP levels and (B) caspase 3 activity; in the Jurkat 
lymphoid leukaemia cell lines. This was evaluated by: (A) CellTiter-Glo® assay and (B) NucView caspase 3 activity assay. Cells were 
treated with CSP, CYCLO or CLB and polyphenols alone and in combination for 24 h using their lowest-significant doses (LSD); together 
with a vehicle control. All data was normalised to the vehicle control which was assigned (A) 100% cell viability and (B) 0% apoptosis. 
The data was expressed as medians and ranges (N = 4). Effects of combination treatments were statistically classified as synergistic (*) 
causing a decrease in ATP levels (A) and an increase in caspase 3 activity (B); or antagonistic (#) causing an increase in ATP levels (A) 
and a decrease in caspase 3 activity (B); when compared to vehicle control, drugs alone and expected values of combination treatments. 
Statistical significant was set at P ≤ 0.05.
Oncotarget4574www.oncotarget.com
Figure 2: The effect of cisplatin (CSP), cyclophosphamide (CYCLO) and chlorambucil (CLB) when used in combination with quercetin 
(QUE), apigenin (AP), emodin (EMO), rhein (RH) or cis-stilbene (CIS) on (A) ATP levels and (B) caspase 3 activity; in the myeloid 
leukaemia cell line (THP-1). This was evaluated by: (A) CellTiter-Glo® assay and (B) NucView caspase 3 activity assay. Cells were 
treated with CSP, CYCLO or CLB and polyphenols alone and in combination for 24 h using their lowest-significant doses (LSD); together 
with a vehicle control. All data was normalised to the vehicle control which was assigned (A) 100% cell viability and (B) 0% apoptosis. 
The data was expressed as medians and ranges (N = 4). Effects of combination treatments were statistically classified as synergistic (*) 
causing a decrease in ATP levels (A) and an increase in caspase 3 activity (B); or antagonistic (#) causing an increase in ATP levels (A) 
and a decrease in caspase 3 activity (B); when compared to vehicle control, drugs alone and expected values of combination treatments. 
Statistical significant was set at P ≤ 0.05.
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Figure 3: The effect of cisplatin (CSP), cyclophosphamide (CYCLO) and chlorambucil (CLB) when used in combination with quercetin 
(QUE), apigenin (AP), emodin (EMO), rhein (RH) or cis-stilbene (CIS) on (A) ATP levels and (B) caspase 3 activity; in non-tumour control 
cells (CD133+ HSC). This was evaluated by (A) CellTiter-Glo® assay and (B) NucView caspase 3 activity assay Cells were treated with 
CSP, CYCLO or CLB and polyphenols alone and in combination for 24 h using their lowest-significant doses (LSD); together with a vehicle 
control. All data was normalised to the vehicle control which was assigned 100% cell viability (A) and 0% apoptosis (B). The data was 
expressed as medians and ranges (N = 4). Effects of combination treatments were statistically classified as synergistic (*) causing a decrease 
in ATP levels (A) and an increase in caspase 3 activity (B); or antagonistic (#) causing an increase in ATP levels (A) and a decrease in 
caspase 3 activity (B); when compared to vehicle control, drugs alone and expected values of combination treatments. Statistical significant 
was set at P ≤ 0.05.
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Figure 4: The  effect of two alkylating agents: cisplatin (CSP) and cyclophosphamide (CYCLO)  on caspases 8 and 9 
activity when used in combination with quercetin (QUE), apigenin (AP), emodin (EMO), rhein (RH) or cis-stilbene 
(CIS) in lymphoid leukaemia cell lines (Jurkat and CCRF-CEM); and when used in combination with QUE or AP 
in myeloid leukaemia cell lines (THP-1 and KG-1a). This was evaluated by Caspases-Glo® luminescent 8 and 9 assays. Cells 
were treated with CSP or CYCLO and polyphenols alone and in combination for 24h using their lowest-significant doses (LSD). Data 
were normalised to the vehicle control, which was assigned a zero luminescence (RLU). The data was expressed as medians with ranges 
(N = 4). Effects of combination treatments were statistically classified as synergistic (*) causing an increase in apoptosis or antagonistic (#) 
causing a decrease in apoptosis; when compared to vehicle control, drugs alone and expected values of combination treatments. Statistical 
significant was set at P ≤ 0.05. 
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In contrast, cis-stilbene when used with each 
alkylating agent had no effect on cell cycle in either the 
lymphoid or myeloid cell lines (P ≤ 0.05) (Supplementary 
Figure 10 and Table 2). The only exception was seen 
when cis-stilbene was used in combination with cisplatin 
in lymphoid cell lines, where there was S phase cell cycle 
arrest (P ≤ 0.05) (Table 2).
The effect of combination treatments on 
glutathione levels
Glutathione analysis was performed for alkylation 
agents and polyphenol combinations which previously 
showed synergistic effects across both lymphoid and 
myeloid leukaemia cell lines (Figure 5). Following 
apigenin combination treatments with cisplatin or 
cyclophosphamide, glutathione levels were synergistically 
reduced in all leukaemia cell lines (P ≤ 0.05) (Figure 5). 
Similarly a decrease in glutathione levels were also observed 
when quercetin was combined with cisplatin in all leukaemia 
cell lines (P ≤ 0.05) (Figure 5), and with cyclophosphamide 
in lymphoid cell lines only (P ≤ 0.05) (Figure 5). 
Emodin and rhein were also shown to synergistically 
reduce glutathione when used in combination with 
cisplatin and cyclophosphamide in lymphoid cell lines 
(P ≤ 0.05) (Figure 5). However, this effect was reversed in 
THP-1 myeloid cells, with emodin and rhein antagonising 
the action of cisplatin and cyclophosphamide, causing 
a significant increase in glutathione levels (P ≤ 0.05) 
(Figure 5). In contrast, cis-stilbene was shown to synergize 
the action of cisplatin in lymphoid cell lines and reduce 
levels of glutathione; but antagonise the action of cisplatin 
and cyclophosphamide in THP-1 myeloid cell lines and 
cyclophosphamide in all the lymphoid cell lines; and 
significantly elevating the levels of glutathione (P ≤ 0.05) 
(Figure 5). CMFDA staining confirmed these results 
(Supplementary Figure 11), showing similar responses 
observed using the GSH-Glo™ glutathione assay.
The effect of combination treatments on γH2AX 
foci 
DNA damage analysis was undertaken in those 
combination treatments which showed the most promising 
Table 2: The effect of cisplatin (CSP), cyclophosphamide (CYCLO) and chlorambucil (CLB) on cell cycle 
progression, when used in combination with quercetin (QUE), apigenin (AP), emodin (EMO), rhein (RH), 
or cis-stilbene (CIS) in two lymphoid leukaemia cell lines (Jurkat and CCRF-CEM) and two myeloid 
leukaemia cell lines (THP-1 and KG-1a)
Lymphoid Leukaemia Myeloid Leukaemia
Jurkat CCRF-CEM THP-1 KG1a
CSP CYCLO CLB CSP CYCLO CLB CSP CYCLO CLB CSP CYCLO CLB
Quercetin
SYN
Interactive 
S
SYN
InteractiveS
ADD
Non-
Interactive
S
SYN
Interactive 
S
SYN
Interactive 
S
SYN
Interactive 
S
SYN
Interactive 
G2/M
ANTG
No Arrest
SYN
Interactive 
G2/M
SYN
Interactive 
G2/M
ANTG
No Arrest
SYN
Interactive S
Apigenin
SYN 
Interactive 
S
SYN 
Interactive S
SYN 
Interactive S
SYN 
Interactive 
S
SYN 
Interactive 
S
SYN 
Interactive 
S
SYN 
Interactive 
G2/M
SYN 
Interactive 
S & G2/M
SYN 
Interactive 
S & G2/M
SYN 
Interactive 
G2/M
SYN 
Interactive 
G0/ G1
SYN 
Interactive 
G2/M
Emodin
SYN
Interactive 
S
SYN
Interactive 
G0/ G1
ADD
Non-
Interactive
G0/ G1
SYN
Interactive 
S
SYN
Interactive 
S
SYN
Interactive 
S
ANTG
No Arrest
ANTG
No Arrest
SYN
Interactive 
G2/M
ANTG
No Arrest
ANTG
No Arrest
SYN
Interactive
S & G2/M
Rhein
SYN
Interactive 
S
SYN
Interactive 
G0/ G1
SYN
Interactive 
G0/ G1
SYN
Interactive 
S
SYN
Interactive 
S
SYN
Interactive 
S
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
Cis-Stilbene
SYN
Interactive 
S
ANTG
No Arrest
ANTG
No Arrest
SYN
Interactive 
S
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
ANTG
No Arrest
Cell cycle progression was analysed by flow cytometry following propidium iodide staining. Cells were treated with CSP, CYCLO or CLB and 
polyphenols alone and in combination for 24 h using their lowest-significant doses (LSD) as determined by CellTiter-Glo assay, together with a vehicle 
control. The percentage of cells in each phase was analysed with FlowJo software using the Watson (Pragmatic) model. The data were expressed 
as medians with ranges (N = 4). Statistical significance of combination treatments was determined and compared with the vehicle control and the 
individual treatments alone. Statistical significance was set at P ≤ 0.05. The combination effects of drugs were statistically shown to be either: non-
interactive (additive effect), interactive (synergistic (SYN) effect) or no arrest (antagonistic (ANTG) effect) on the cell cycle phases, this has been 
statistically determined as shown in our previous work17.
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synergistic effect in all leukaemia cell lines (Figure 6). 
Cisplatin and cyclophosphamide alone caused an increase 
in levels of DNA damage in all leukaemia cell lines 
(P ≤ 0.05) (Figure 6). Following apigenin combination 
treatment with cisplatin or cyclophosphamide a synergistic 
increase in γH2AX foci was seen in all leukaemia cell 
lines (P ≤ 0.05), shown here in Jurkat cells (Figure 6B). 
Likewise, quercetin synergistically increased γH2AX foci 
when combined with cisplatin in all leukaemia cell lines 
(P ≤ 0.05) and when combined with cyclophosphamide, in 
the lymphoid cell lines (P ≤ 0.05) (Figure 6). 
Emodin and rhein were also shown to synergize 
the formation of γH2AX foci when used in combination 
with both cisplatin and cyclophosphamide, but only in 
lymphoid cell lines (P ≤ 0.05), with no significant effects 
in myeloid cell lines (Figure 6). In contrast cis-stilbene 
synergistically increased γH2AX foci in combination with 
cisplatin in lymphoid cell lines (P ≤ 0.05); but not myeloid 
cell lines (Figure 6). 
DISCUSSION
This study investigated the combined effects of 
five polyphenols (quercetin, apigenin, emodin, rhein, 
and cis-stilbene) on three alkylating agents (cisplatin, 
cyclophosphamide and chlorambucil). Our earlier work 
Figure 5: The effect of two alkylating agents: cisplatin (CSP) and cyclophosphamide (CYCLO) on glutathione (GSH) 
levels when used in combination with quercetin (QUE), apigenin (AP), emodin (EMO), rhein (RH) or cis-stilbene 
(CIS) in two lymphoid (Jurkat and CCRF-CEM); and two myeloid leukaemia cell lines (THP-1 and KG-1a). GSH 
levels were evaluated by the GSH-Glo™ Glutathione. Cells were treated with CSP or CYCLO and polyphenols alone and in combination 
for 24 h using their lowest-significant doses (LSD). Data was normalised to the vehicle control which was assigned 100% of GSH levels. 
The data was expressed as medians and ranges (n = 4). Effects of combination treatments were statistically classified as synergistic (*) 
causing a decrease in GSH levels or antagonistic (#) causing an increase in GSH levels; when compared to vehicle control, drugs alone and 
expected values of combination treatments. Statistical significant was set at P ≤ 0.05.
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Figure 6: (A) The effect of two alkylating agents: cisplatin (CSP) and cyclophosphamide (CYCLO) on γ-H2AX foci formation (DNA 
damage marker) when used in combination with quercetin (QUE), apigenin (AP), emodin (EMO), rhein (RH) or cis-stilbene (CIS); in two 
lymphoid (Jurkat and CCRF-CEM) and two myeloid (THP-1 and KG-1a) leukaemia cell lines.  This was evaluated by the immunofluorescent 
staining using Alexa Fluor® 647 Mouse anti-H2AX (pS139). Cells were treated with CSP, CYCLO or CLB and polyphenols alone and 
in combination for 24 h using their lowest-significant doses (LSD). The data was expressed as medians and ranges (N = 4). Data was 
normalised to the vehicle control which was assigned 0% of γ-H2AX foci formation (DNA damage marker). Effects of combination 
treatments were statistically classified as synergistic (*) causing an increase in the percentage of cells with γ-H2AX foci or antagonistic 
(#) causing a decrease in the percentage of cells with γ-H2AX foci; when compared to vehicle control, drugs alone and expected values 
of combination treatments. Statistical significant was set at P ≤ 0.05. (B) An example of immunofluorescent detection of DNA damage 
(measured as γ-H2AX foci) for Jurkat lymphoid leukaemia cells when treated with LSDs of cisplatin (CSP) and cyclophosphamide 
(CYCLO) alone and in combination with apigenin (AP) for 24 h. Cells with ≥5 foci (red arrows) are identified as having DNA damage. 
Images were captured in bright filed using (Cell-F software, Olympus). Scale bar = 100 µm.
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has shown that these polyphenols can induce apoptosis 
and arrest cell cycle in leukaemia cell lines [11]. Here, 
we show the effects of combination treatments on ATP 
levels, the induction of apoptosis and cell cycle arrest 
in non-tumour control cells and leukaemia cell lines. In 
non-tumour control cells, all polyphenols were shown to 
inhibit the toxic effects of all alkylating agents, suggesting 
that polyphenols are protective of normal cells. 
In lymphoid leukaemia cells, quercetin, apigenin, 
emodin and rhein synergistically enhanced cisplatin and 
cyclophosphamide activity, reduced ATP levels, causing 
cell cycle arrest and inducing apoptosis. Similarly, 
chlorambucil acted synergistically with apigenin or rhein. 
However, in myeloid leukaemia cells all three alkylating 
agents displayed differential effects, some synergistic and 
some antagonistic, when combined with polyphenols.
Interestingly, the most promising polyphenols for 
the combination with all alkylating agents in all leukaemia 
cell lines, were apigenin and quercetin; and the least 
effective polyphenol was cis-stilbene. This is a novel 
finding, and to date no previous studies have combined 
cyclophosphamide and chlorambucil with our selected 
polyphenols. There is however, previous work which 
combined cisplatin with apigenin, quercetin and emodin 
in solid tumours [25–27]. Apigenin has been shown to 
enhance the action of cisplatin in head and neck squamous 
cells (SCC25) [25], human nasopharyngeal (CNE-2Z) [26] 
and laryngeal carcinoma (Hep-2) cell lines [27]. A similar 
effect was observed here, with apigenin enhancing the 
action of all three alkylating agents in all leukaemia cell 
lines, synergistically reducing ATP and glutathione levels, 
inducing DNA damage and cell cycle arrest.
Similarly, quercetin has previously been shown 
to enhance the activity of cisplatin, and synergistically 
induce apoptosis in a number of solid tumours [18–24]. 
Furthermore, the combination of cisplatin and quercetin 
was also been shown to induce synergistic arrest of the 
cell cycle at S phase in human malignant mesothelioma 
cells (SPC212 and SPC111) [21], and at G0/G1 phase, by 
elevation of p16INK4A expression in human hepatocellular 
carcinoma cells (HepG2) [24].
Cisplatin has been previously shown to be 
potentiated by other polyphenols such as emodin, in 
non-small cell lung cancer (NSCLC) with HER-2/neu-
overexpressing [28], merkel cell carcinoma (MCC) 
[29], human ovarian tumour cell lines (A2780) [30], and 
gallbladder carcinoma cells (SGC996) [31, 32]. Likewise, 
here cisplatin and cyclophosphamide in combination with 
quercetin synergistically reduced ATP levels, induced 
apoptosis, and accumulated the cells at S phase and/or 
G2/M phase in both lymphoid and myeloid cell lines. The 
only exception was seen in myeloid cell lines where an 
antagonistic effect was seen when cyclophosphamide was 
combined with quercetin. 
This current study showed that emodin and rhein in 
combination with alkylating agents caused a synergistic 
reduction in ATP levels, induction of apoptosis and 
accumulation of cells at S phase in lymphoid leukaemia 
cell lines; whilst having a differential effects in myeloid 
leukaemia cell lines, some of which were antagonistic. 
Demonstrating the therapeutic effects of alkylating agents 
in combination emodin and rhein may be dependent on 
the cell lineage; and could be useful in the treatment of 
lymphoid leukaemia, but may be detrimental in myeloid 
leukaemia.
Cis-stilbene was the least effective polyphenol 
producing mostly antagonistic effects when used in 
combination with cyclophosphamide and chlorambucil 
in both lymphoid and myeloid leukaemia cells, the only 
exception was seen when used in combination with 
cisplatin which produced synergistic effects in lymphoid 
cells. 
In the current study, all the synergistic responses of 
polyphenols with either cisplatin or cyclophosphamide 
were accompanied by a down-regulation of glutathione 
and increased DNA damage. This resulted in a synergistic 
increase in caspase 8 and 9 when combined with quercetin 
or apigenin, and caspase 9 when combined with emodin 
or rhein in each investigated leukaemia cell line. This 
ultimately led to a synergistically increased in caspase 3 
activity and apoptotic cell death. 
These results suggest that synergistic effects 
of alkylating agents with quercetin or apigenin in 
both myeloid and lymphoid cell lines is dependent 
on activation of both extrinsic and intrinsic apoptotic 
pathways; whilst their effects with emodin or rhein are 
dependent on caspase 9, and the activation of the intrinsic 
apoptosis pathways. However, as these cells are p53 
null [33–35], this could not occur via the p53 pathway; 
suggesting that their action is via p53 independent Bad 
and/or Bak activity. Previous studies have shown similar 
effects with cisplatin when combined with quercetin, 
causing a synergistic induction of the intrinsic apoptotic 
pathway, an increase in caspase 9 and 3 activity. This was 
shown to occur via a down-regulation of Bcl-xl and Bcl-
2, and an increase in cytochrome-C in a number of solid 
tumour cells [19–21].  Furthermore, synergistic treatments 
in human non-small cell lung carcinoma (NCL-H-520) 
cell lines demonstrated interactive effects on cell 
cycle resulting in S phase and/or G2/M phase arrest; 
accompanied by the presence of γH2AX foci, which are 
indicative of DNA damage [19]. 
Current studies report that the measurement of 
γH2AX foci are useful in determining whether or not 
drugs reach a tumour, are convert to their activated 
forms, and are capable of inducing DNA damage [36, 
37]. Rajendran et al, (2011) suggested that the use of 
combination treatments which cause DNA damage and 
interfere with DNA repair in cancer cells could be very 
effective and produce synergistic effects [38]. In this 
regard, the synergistic drug combinations reported here 
are worthy of further investigation in leukaemia.
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In contrast, the antagonistic responses seen here 
when cisplatin and cyclophosphamide were combined 
with emodin, rhein or cis-stilbene in myeloid cell lines 
were associated with elevation in glutathione levels, and 
no γ-H2AX foci and hence no DNA damage, or cell cycle 
arrest. There is limited evidence that shows polyphenols 
can block the activity of standard chemotherapy. However, 
Cˇipak et al 2003, showed apigenin, galangin and chrysin 
inhibited the action of cisplatin and doxorubicin, in 
murine leukaemia (L1210) cells [39]. This antagonistic 
effect has been attributed to the polyphenols’ antioxidant 
activity, which protecting the cells against cisplatin and 
doxorubicin generated reactive oxygen species (ROS). It 
was suggested that apoptosis was inhibited, by suppression 
of ROS production and the activation of the c-Jun 
NH2-terminal kinase (JNK) pathway [39]. Likewise, it 
was reported that rutin hydrate, quercetin dehydrate, 
hydrocaffeic acid, gallic acid and tannic acid antagonised 
the induction of apoptosis caused by bortezomib in 
multiple myeloma cells (MC/CAR, RPMI8226 and U266) 
[40]. However, the exact mechanism action of these 
polyphenols on bortezomib remains unknown.
Earlier work has also reported polyphenols can 
act as both an antioxidants and pro-oxidants, depending 
on doses and cellular conditions. This suggests that 
polyphenols are capable of modulating antioxidant redox 
systems, such as glutathione [41–43], and thus could have 
a chemopreventive effect. Alternatively, the anti-cancerous 
effects of polyphenols could be attributed to their pro-
oxidant activity [41–43].
Here we have shown the synergism and antagonism 
mechanisms of action of our selected polyphenols with 
cisplatin and cyclophosphamide, are strongly dependent 
on modulation of glutathione levels, caspase activity 
and DNA damage within each studies cell lines. These 
findings are supported by earlier studies, where cisplatin 
when combined with quercetin [44], apigenin [25] or 
emodin [31] synergistic inhibited cell proliferation and 
induced apoptosis through the elevation of intracellular 
ROS and the reduction glutathione levels. This caused 
mitochondrial transmembrane potential dissipation and 
activated of the intrinsic apoptotic pathway via release 
of cytochrome-C, down-regulation of Bcl-X(L) and up-
regulation Bax, followed by caspase 9 and 3 activation 
and apoptosis in ovarian [44], head and neck squamous 
carcinoma (SCC25) [25] and gallbladder (SGC996) [31] 
cancer cell lines.
Here, lymphoid leukaemia cell lines demonstrated 
greater synergistic responses to the combination 
of alkylating agents and polyphenols than myeloid 
leukaemia cell lines. Indeed, our previous work has 
shown that in leukaemia cell lines, basal glutathione 
levels correlate strongly with responses to combination 
treatments of topoisomerase inhibitors and polyphenols 
[17]. In particular, we previously reported that low basal 
glutathione levels were present in lymphoid leukaemia cell 
lines compared to non-tumour control cells and myeloid 
cell lines; and lymphoid leukaemia cell lines were more 
sensitive to this combination treatment [17], whereas 
higher basal glutathione levels in myeloid leukaemia 
cells and non-tumour controls cells was associated with 
resistance to combination treatments of polyphenols and 
topoisomerase inhibitors [17]. This may explain why 
lymphoid cell lines here were more sensitive to alkylating 
agents/polyphenol combination treatments than the 
myeloid leukaemia cell lines. Traverso et al, 2013 reported 
that cancers with high levels of glutathione such as lung, 
ovarian, breast, and haematological malignancies have 
an increase in the antioxidant capacity and this prevented 
oxidative stress and DNA damage, and inhibited apoptosis; 
and as a result, this could also lead to drug-resistance [42]. 
Furthermore, it is reported that cancers with low levels of 
glutathione such as melanoma have a decrease of cellular 
antioxidant capacity and an increase in oxidative stress, 
DNA damage and cell death; and this can lead to increases 
in the sensitivity of these cancers to treatment [42]. Thus, 
cancer cell types and basal glutathione levels may be 
relevant when designing new clinical chemotherapy 
regimens. It is apparent that polyphenols have the capacity 
to reduce basal glutathione levels in cancer cells and 
increase susceptibility to chemotherapy treatment. 
Additionally, our previous work reported that 
glutathione depletion helped to increase the therapeutic 
efficacy of topoisomerase inhibitors [17, 45]. It is believed 
that the reduction of glutathione can predispose cells to 
apoptosis, directly trigger the formation of permeability 
transition pore, and the activation of execution caspases 
[46]. Furthermore the over expression of anti-apoptotic 
Bcl-2, and the inhibition of mitochondrial-induced 
apoptosis, are strongly linked to the antioxidant property 
of glutathione [46]. Therefore, it is necessary to decrease 
glutathione levels, in order to increase the efficacy of 
chemotherapy agents and reduce multidrug resistance in 
cancer cells [47–49].  
In conclusion, this study suggests that the 
combination of alkylating agents, in particular cisplatin 
with polyphenols show promising anti-tumour activities in 
lymphoid leukaemias. However, the potential antagonistic 
effects of some polyphenols on certain alkylating agents 
need careful consideration and further investigation. 
MATERIALS AND METHODS
Leukaemia cell lines 
Four human leukaemia cell lines were used for 
this study: Two lymphoid leukaemia cell lines (Jurkat 
(peripheral blood T cell leukaemia) (ATCC: TIB-152, 
Middlesex, UK) and CCRF-CEM (acute lymphoblastic 
leukaemia) (ATCC: CCL-119, Middlesex, UK)); which 
had been previously shown to be sensitivity to polyphenols 
treatments [17]; together with two myeloid leukaemia cell 
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lines (THP-1 (acute monocytic leukaemia) (ATCC: TIB- 
202, Middlesex, UK) and KG-1a (acute myelogenous 
leukaemia) (ATCC:CCL-243)) which had been previously 
shown to be resistance to polyphenol treatment [17].  Non-
tumour control hematopoietic stem cells from cord blood 
(CD34+HSC and CD133+HSC) (Stem cell Technologies, 
Grenoble, France) were also included in the study. All 
cells were tested for mycoplasma contamination using the 
MycoAlert TM mycoplasma detection kit (Lonza, MD, 
USA) and were negative throughout the study. 
Culture conditions
Cells were maintained in Roswell Park Memorial 
Institute (RPMI) medium 1640 (Invitrogen, Paisley, UK) 
supplemented with 10% (v/v) foetal bovine serum, 1.5 mM 
L-glutamine and 100 μg/ml penicillin/streptomycin at 
37º C with 5% CO2. 
Treatment regimes
Two lymphoid leukaemia cell lines (Jurkat and 
CCRF-CEM), two myeloid leukaemia cell lines (THP-
1 and KG-1a); and two non-tumour control cells 
(CD34+HSC and CD133+HSC) were treated with each 
polyphenol and each alkylating agent: cisplatin (CSP), 
cyclophosphamide (CYCLO), chlorambucil (CLB) 
(Sigma, Poole, UK) alone or in combination, along with a 
vehicle control for 24 h. All treatments were performed in 
triplicate with four technical replicated. 
Quercetin (QUE) (Enzo Life Sciences, Exeter, UK), 
apigenin (AP), emodin (EMO), rhein (RH) and cis-stilbene 
(CIS) (Sigma, Poole, UK) were prepared as described 
previously [11]. Cisplatin was dissolved in 1:1 v/v water: 
ethanol; and cyclophosphamide and chlorambucil were 
dissolved in water. Stock solutions (25 mM) of each 
polyphenol were prepared with 10% (v/v) ethanol (Sigma) 
in serum free media (Invitrogen, Paisley, UK) to generate 
treatment concentrations between 0.005 and 50 μM. All 
polyphenols were HPLC analytical grade and were 90-
97% pure. In addition, 0.1% (v/v) ethanol vehicle controls 
were prepared for each treatment in all cell lines. 
Dose response curves were generated for each 
alkylating agent. These were used to determine the IC50 
dose (which statistically reduced ATP levels by 50%) and 
lowest significant dose (LSD) (which is the lowest dose 
which statistically reduced ATP levels and induced caspase 
3 activity when compared to the vehicle control at 24 h) 
(Table 1). Significance was determined using a Kruskal-
Wallis with a Conover-Inman Post hoc-test. The LSDs 
for each polyphenol were determined in our previous 
study [17]. These LSD doses were used for subsequent 
polyphenol/ chemotherapy combination treatments. 
Cells were treated with each polyphenol and each 
alkylating agent: cisplatin (CSP), cyclophosphamide 
(CYCLO), chlorambucil (CLB) alone or in combination 
at their LSDs, along with a vehicle control, for 24 h. All 
treatments were performed in triplicate with four technical 
replicates. Following treatments with each alkylating 
agent, ATP levels, cell cycle progression, induction 
of apoptosis and caspase 3 activity were assessed. 
Subsequently, assessment was made of glutathione levels 
and DNA damage (measured as γH2AX foci) following 
cisplatin and cyclophosphamide treatments.
CellTiter-Glo® luminescent cell ATP viability 
assay 
The CellTiter-Glo® luminescent assay measure ATP 
levels and is indicative of cell viability and proliferation. 
Cells were seeded at 2.5 × 103 cells per well of white 
96-well plates (Fisher Scientific, Loughborough, UK) 
and treated with each polyphenols and alkylating agents 
alone and in combination for 24 h, together with a 0.1% 
(v/v) ethanol vehicle control. Following treatments, the 
CellTiter-Glo® luminescent cell viability assay (Promega) 
was used to measure ATP levels, as per manufacturer’s 
instructions. Dose response curves were generated for 
each alkylating agent. These were used to determine 
the lowest significant dose (LSD) which statistically 
reduced ATP levels when compared to the vehicle control 
at 24 h (Table 1). These LSD for ATP were used for 
subsequent polyphenol/chemotherapy combination work 
on cell viability, cell-cycle progression, DNA damage and 
glutathione levels. 
Apoptosis and cell cycle analysis
Cells were seeded at 0.5 × 106 cells per well in 12-
well plates and treated with polyphenols and alkylating 
agents alone or in combination for 24 h, together with a 
0.1% (v/v) ethanol vehicle control. Following treatments, 
caspase 3 activity was determined using Nucview caspase 
3 activity assay using flow cytometry, as described 
previously [17]. Dose response curves were generated for 
each alkylating agent. These were used to determine the 
lowest significant dose (LSD) which statistically increased 
caspase 3 activity compared to the vehicle control at 
24 h (Table 1). These LSD doses for caspase 3 activity 
were used for subsequent polyphenol/chemotherapy 
combination treatments on the morphological assessment 
of apoptosis using Hoechst 33342/propidium iodide 
staining and fluorescence microscopy; and for the 
investigation of cell cycle progression using propidium 
iodide staining and flow cytometry, as described 
previously [17]. 
Caspases 8 and 9-Glo® luminescence assays
Cells were seeded into white 96-well plates (Fisher 
Scientific, Loughborough, UK) at 2.5 × 103 cells per 
well and treated with two alkylating agents: cisplatin and 
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cyclophosphamide. These alkylating agents were selected 
as they showed a greater synergistic effect when used in 
combination with polyphenols; across both lymphoid and, 
myeloid leukaemia cell lines. These alkylating agents were 
used alone and in combination with those polyphenols that 
previously showed a synergistic effect and were used at 
their LSDs for 24 h, together with a 0.1% (v/v) ethanol 
vehicle control. Following treatment Caspase-Glo® 8 and 
9 assays were used as per manufacturerʼs instructions 
(Promega, Southampton, UK) to determine caspase 8 and 
9 activity. Luminescence was measured using a Wallac 
Victor 2 1420 and were normalised to vehicle controls.
Measurement of cell glutathione (GSH) levels 
GSH-Glo™ glutathione assay
Cells were seeded at 2.5 × 103 cells per well into 
white 96-well plates and treated with two alkylating agents 
(cisplatin and cyclophosphamide) alone or in combination 
with polyphenols at their LSD for 24 h, together with 
vehicle control. Following treatment, glutathione 
levels were measured using the GSH-GloTM glutathione 
luminescent assay as per the manufacturer’s instructions 
and reported previously [17]. The luminescent signal was 
measured using a Wallac Victor 2 1420 and normalised to 
the vehicle control.
Cell Tracker™ Green 5-Chloromethylfluorescein 
Diacetate (CMFDA)-glutathione staining 
Cells were seeded into white 24-well plates (Fisher 
Scientific, Loughborough, UK) at 1.0 × 103 cells per 
well and treated with two alkylating agents (cisplatin 
and cyclophosphamide) and polyphenols alone and 
in combination at their LSD for 24 h, together with a 
vehicle control; then incubated at 37° C with 5% CO2 
for 24 h. Following treatments, cells were stained with 
Cell Tracker™ Green CMFDA (Molecular Probes) to 
detect and quantify GSH levels (specificity 95%) and 
counterstained with Hoechst 33342 stain (Sigma, Poole 
UK) to localize the cell nuclei as described previously 
[17]. Images were captured using CellF imaging software 
(Olympus). CMFDA green staining was localised mainly 
in the cytoplasm, as well in the nucleus of the live cells 
only, which commonly have high glutathione level, while 
it is depleted in apoptotic and dead cells. Hoechst 33342 
blue staining was commonly localised in the nuclei of both 
live and dead cells. Two hundred cells (green and blue) 
were counted and then percentage of (green stained) GSH 
positive cells was determined for each sample. 
Measurement of DNA damage by γH2AX foci 
detection 
The formation of γH2AX foci is indicative of 
DNA damage. The Alexa Fluor 647 Mouse anti-γH2AX 
(pS139) (BD Pharmingen, Oxford, UK) specifically 
targets phosphorylation of Ser-139 at the C-terminal 
region of γH2AX enabling the visualisation of γH2AX 
by immunofluorescence. Cells were seeded at 1.0 × 103 
cells per well into a BD Falcon 96-well imaging plate 
(BD Pharmingen) and treated with two alkylating 
agents: cisplatin and cyclophosphamide) alone and in 
combination with each polyphenol at their LSD for 24 h, 
together with vehicle control. Following treatments, cells 
were centrifuged at 400 × g for 10 min then washed in 
PBS and fixed in BD Cytofix fixation buffer for 10 min 
(BD Pharmingen). Cells were washed twice in PBS 
and permeabilized in 90% methanol (Sigma) for 5 min. 
Following washes, cells were incubated in 50 μl Alexa 
Fluor 647 Mouse anti-γH2AX (pS139) (1:10 v/v) at 
room temperature for 1 h in the dark. Cells were washed 
3 times in PBS and counter-stained in 100μl of 2 mg/ml 
Hoechst 33342 stain for 15 min.
Cells were visualised using inverted fluorescence 
microscopy (Olympus IX-81) and analysed using Cell-F 
software (Olympus). Cells with greater than six γ-H2AX 
foci were considered as having DNA damage. The 
number of cells with DNA damage (>6 foci) or without 
DNA damage (<6 foci) were counted. Two hundred 
cells per treatment were counted and percentage of cells 
with substantial DNA damage determined. Images were 
captured using an inverted fluorescence microscopy and 
the Cell-F software.
Statistical analysis 
The median with range was calculated for each 
assay. Stats Direct software (Stats Direct Ltd, Altrincham, 
UK) was used to test whether data followed a normal 
distribution using normality testing in Stats Direct. As 
data was non-parametric, a Kruskal-Wallis and Conover-
Inman post-hoc test was used to determine the statistical 
significance of the data. Results were considered 
statistically significant when P ≤ 0.05. 
The effect of combination chemotherapy and 
polyphenol treatment on ATP levels, apoptosis, glutathione 
levels and DNA damage were classified as: synergistic (*) 
or antagonistic (#) as described previously [17]. All results 
were considered statistically significant when P ≤ 0.05. 
Cell-cycle analysis was performed by determining 
the percentage of cells in each phase using the FlowJo 
software using the Watson pragmatic model. The data was 
expressed as medians with ranges (N = 4). The statistical 
significance of individual drugs was determined firstly 
in comparison to the vehicle control using a Kruskal-
Wallis and Conover Inman post-hoc tests. The statistical 
significance of combined polyphenol and drugs treatments 
was determined in comparison to the vehicle control and 
the individual treatments alone. The effect of combination 
treatments on cell-cycle was classified either as: interactive 
(synergetic), non-interactive or no arrest (antagonistic) 
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using the method described previously [17]. Statistical 
significance was set at P ≤ 0.05.
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